Developer docs
API playgroundTry for free, no card

Search company profiles

Okomera

Full company profile

uuid0000tkv

Namestring
Okomera
Legal namestring
OKOMERA
Websiteurl
okomera.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Okomera is a Paris-based functional precision medicine biotech founded in 2020 that builds miniaturized tumor-on-chip technology paired with AI imaging analysis to predict personalized cancer drug responses from patient-derived biopsies. Its core product, the Okomera Platform, uses droplet-based microfluidics to encapsulate patient-derived 3D organoids and spheroids, enabling automated screening of up to 800 conditions on 1,000 microtumors per batch with a turnaround of approximately one week and a minimum input of 50 cells — figures the company positions as 6x faster and 1000x lower in sample requirement than incumbent methods. The technology originates from research at Ecole Polytechnique and Institut Pasteur, and is being extended into CRISPR screening assays through a collaboration with CRCM Marseille funded by Bpifrance.

The company operates a B2B enterprise model targeting pharmaceutical and biotech drug developers for preclinical and target-identification studies, academic cancer research centers, and clinical oncologists for treatment-selection support. Revenue is generated through professional services for drug discovery (preclinical screening, CRISPR screening, T-cell potency testing) and recurring subscription-style clinical decision support for hospitals, with pricing opaque and provided on a quote basis. The company is venture-backed (≈€11.5M disclosed, including a December 2023 €10M round led by Resonance with Berkeley SkyDeck, Polytechnique Ventures, and SkyDeck Berkeley, plus a €1.5M Bpifrance grant in October 2024), employs 11–50 people, and operates from a single Paris headquarters with no disclosed commercial geographic footprint beyond France.

Strategic positioning rests on a tightly integrated stack of proprietary microfluidics, AI-driven image analysis, and access to tier-1 oncology partners (Institut Curie, Gustave Roussy, Cancer Research UK, UC Berkeley), combined with peer-reviewed scientific output (SLAS 2023 Ignite Award, publications in iScience, Nature Communications, Cell Reports, Science Advances). Distribution is direct enterprise sales with no disclosed resellers, and customer logos are not publicly named, implying an early commercial stage where validation partners double as reference accounts.

Short descriptiontext

Okomera is a Paris-based biotech that combines miniaturized tumor-on-chip microfluidics with AI imaging to deliver personalized cancer drug-response testing from patient biopsies in under a week, serving pharmaceutical, biotech, academic, and clinical oncology customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tumor-on-chip technology, precision medicine oncology, organoid drug screening, cancer drug discovery, microfluidics platform
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAE
Clinical Decision Support & Workflow Integration (EHR/oncology systems)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Health Services8000
Product category
Functional Precision Medicine
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Discovery Services
TypeProfessional Services
Description

Provides pharmaceutical and biotech companies with preclinical drug screening services using patient-derived organoids and spheroids to identify effective cancer treatments.

okomera.com
2Clinical Decision Support
TypeSubscription Recurring
Description

Offers personalized treatment intelligence services for clinicians to guide cancer treatment decisions based on individual patient drug response patterns.

okomera.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Okomera develops and operates a functional precision medicine platform that combines miniaturized tumor-on-chip microfluidic technology with AI imaging analysis to deliver rapid, personalized drug response testing from patient-derived biopsies. The platform serves pharmaceutical and biotech companies for preclinical drug screening and cancer research, and supports clinical oncologists with treatment selection intelligence, returning results in under one week from as few as 50 cells.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 1-week turnaround from biopsy to treatment decision
+4 more records
Product overview1 text field

Okomera offers a unified functional precision medicine platform for personalized cancer care. The core Okomera Platform combines miniaturized tumor-on-chip technology and AI imaging to transform complex tumor biological responses into actionable treatment intelligence. The platform enables clinicians and drug developers to test up to 800 different conditions on 1000 microtumors from patient-derived biopsies, delivering results in under a week with only 50 cells needed. Applications span drug development, preclinical studies, and clinical decision-making, covering use cases including CRISPR screening, T-Cell Potency testing, and drug screening.

Product and service3 records
1Okomera Platform
CategoryFunctional Precision Medicine Platform
Description

Functional precision medicine platform combining miniaturized tumor-on-chip technology with AI imaging to test up to 800 conditions on 1000 microtumors from patient-derived biopsies, returning personalized drug response patterns in under one week from as few as 50 cells. Targeted at pharmaceutical and biotech drug developers, academic cancer researchers, and clinical oncology institutions for drug discovery, preclinical studies, and clinical decision-making applications including CRISPR screening, T-Cell Potency testing, and drug screening.

2Drug Discovery Services
CategoryDrug Discovery and Preclinical Services
Description

Preclinical drug screening services using patient-derived organoids and spheroids to help pharmaceutical and biotech companies identify effective cancer treatments, evaluate drug efficacy, and identify therapeutic targets with high-throughput microfluidic screening. Customers contract for project-based screening engagements on the Okomera Platform.

3Clinical Decision Support (Personalized Treatment Intelligence)
CategoryClinical Decision Support Services
Description

Recurring personalized treatment intelligence service for clinicians and cancer centers that delivers patient-specific drug response patterns from biopsy material to guide cancer therapy selection and address the roughly 50% first-line treatment failure rate. Sold on a recurring basis to hospitals and clinical oncology institutions.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1CRCM (Centre de Recherche en Cancérologie de Marseille)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-21
Description

Cancer research center in Marseille collaborating on the development of novel CRISPR screening assay for cancer drug discovery using microfluidics and AI integration.

prnewswire.co.uk
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partner contributing breakthrough science and technology foundations for Okomera's platform. Provides ongoing research collaboration and access to scientific expertise in microfluidics and bioengineering.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partner providing foundational scientific research for Okomera's tumor-on-chip technology. Key source of breakthrough science in cancer biology and organoid research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading French cancer research center and university hospital. Strategic partner for clinical validation and research collaboration in oncology applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Premier European cancer research and treatment center. Strategic partner for clinical applications and validation of personalized medicine approaches.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Major UK-based cancer research charity and funder. Research partner for cancer biology studies and drug discovery applications.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

US academic partner for research collaboration in bioengineering and cancer technology applications.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dutch organ-on-chip company offering microfluidic 3D tissue models for drug discovery and toxicity screening. Closest direct competitor to Okomera in droplet-microfluidics and organoid-based drug response testing, serving the same pharma/biotech buyer set.

TypeDirect peer
Description

US organ-on-chip platform using microfluidic 'chips' to model human organ biology for pharmaceutical R&D. Comparable in combining microfluidic chips with biological assays and AI/ML readout for drug discovery, targeting similar enterprise pharma customers.

3CN Bio Innovations
TypeDirect peer
Description

UK-based organ-on-chip company with single- and multi-organ microphysiological systems used for drug discovery and disease modeling. Overlaps directly with Okomera in microfluidic platforms for preclinical drug screening and human-relevant disease models.

TypeDirect peer
Description

Swiss 3D organoid and spheroid screening company offering high-throughput in vitro models for drug discovery and safety assessment. Directly comparable to Okomera's use of patient-derived spheroids for drug response testing and preclinical applications.

5Hubrecht Organoid Technology (HUB)
TypeDirect peer
Description

Dutch pioneer of adult stem cell-derived organoids, offering organoid biobanks and drug screening services. Comparable to Okomera in applying patient-derived organoids to functional precision medicine and oncology drug response prediction.

TypeBroad incumbent
Description

Global preclinical CRO offering oncology services including organoid and PDX drug screening for pharma/biotech customers. Comparable buyer set and oncology drug-discovery use cases, but broader portfolio including in vivo models and clinical CRO services.

7Tempus Labs
TypeBroad incumbent
Description

US precision oncology company combining molecular profiling, AI, and clinical data to support therapy selection in oncology. Overlaps with Okomera in AI-enabled personalized oncology decision support, but at much larger scale and with DNA/molecular rather than functional assay approaches.

TypeBroad incumbent
Description

Genomics-driven oncology diagnostics company (Roche subsidiary) providing molecular profiling to guide cancer therapy. Comparable in serving the personalized oncology therapy-selection use case that Okomera targets, though via molecular rather than functional assays.

TypeEmerging player
Description

Israel-based AI drug discovery company using machine-learning models trained on proprietary biological data to support pharma R&D and target identification. Comparable emerging player applying AI to accelerate oncology drug discovery, with potential to converge with functional assay providers like Okomera.

TypeRegional player
Description

Swiss clinical-stage biotech developing DARPin-based therapeutics for oncology, with adjacent interest in functional cancer biology. Comparable in operating in the European precision oncology ecosystem and engaging the same pharma and academic partners as Okomera, though focused on therapeutic development rather than screening platforms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Okomera

Functional Precision Medicineokomera.com

Okomera is a Paris-based biotech that combines miniaturized tumor-on-chip microfluidics with AI imaging to deliver personalized cancer drug-response testing from patient biopsies in under a week, serving pharmaceutical, biotech, academic, and clinical oncology customers.

What Okomera does

Okomera is a Paris-based functional precision medicine biotech founded in 2020 that builds miniaturized tumor-on-chip technology paired with AI imaging analysis to predict personalized cancer drug responses from patient-derived biopsies. Its core product, the Okomera Platform, uses droplet-based microfluidics to encapsulate patient-derived 3D organoids and spheroids, enabling automated screening of up to 800 conditions on 1,000 microtumors per batch with a turnaround of approximately one week and a minimum input of 50 cells — figures the company positions as 6x faster and 1000x lower in sample requirement than incumbent methods. The technology originates from research at Ecole Polytechnique and Institut Pasteur, and is being extended into CRISPR screening assays through a collaboration with CRCM Marseille funded by Bpifrance.

The company operates a B2B enterprise model targeting pharmaceutical and biotech drug developers for preclinical and target-identification studies, academic cancer research centers, and clinical oncologists for treatment-selection support. Revenue is generated through professional services for drug discovery (preclinical screening, CRISPR screening, T-cell potency testing) and recurring subscription-style clinical decision support for hospitals, with pricing opaque and provided on a quote basis. The company is venture-backed (≈€11.5M disclosed, including a December 2023 €10M round led by Resonance with Berkeley SkyDeck, Polytechnique Ventures, and SkyDeck Berkeley, plus a €1.5M Bpifrance grant in October 2024), employs 11–50 people, and operates from a single Paris headquarters with no disclosed commercial geographic footprint beyond France.

Strategic positioning rests on a tightly integrated stack of proprietary microfluidics, AI-driven image analysis, and access to tier-1 oncology partners (Institut Curie, Gustave Roussy, Cancer Research UK, UC Berkeley), combined with peer-reviewed scientific output (SLAS 2023 Ignite Award, publications in iScience, Nature Communications, Cell Reports, Science Advances). Distribution is direct enterprise sales with no disclosed resellers, and customer logos are not publicly named, implying an early commercial stage where validation partners double as reference accounts.

Okomera firmographics

Firmographics
Name
Okomera
Legal name
OKOMERA
Website
https://okomera.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Okomera is a Paris-based biotech that combines miniaturized tumor-on-chip microfluidics with AI imaging to deliver personalized cancer drug-response testing from patient biopsies in under a week, serving pharmaceutical, biotech, academic, and clinical oncology customers.
Ownership category
akta.pro rank

Okomera industry classification

Industry
Product category
Functional Precision Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAE
Clinical Decision Support & Workflow Integration (EHR/oncology systems)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Tumor-on-chip technology
  • Precision medicine oncology
  • Organoid drug screening
  • Cancer drug discovery
  • Microfluidics platform

Where Okomera is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Okomera business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Drug Discovery Services: Provides pharmaceutical and biotech companies with preclinical drug screening services using patient-derived organoids and spheroids to identify effective cancer treatments.
  2. Clinical Decision Support: Offers personalized treatment intelligence services for clinicians to guide cancer treatment decisions based on individual patient drug response patterns.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Okomera product offering

Product offering

Core offering

Okomera develops and operates a functional precision medicine platform that combines miniaturized tumor-on-chip microfluidic technology with AI imaging analysis to deliver rapid, personalized drug response testing from patient-derived biopsies. The platform serves pharmaceutical and biotech companies for preclinical drug screening and cancer research, and supports clinical oncologists with treatment selection intelligence, returning results in under one week from as few as 50 cells.

Product overview

Okomera offers a unified functional precision medicine platform for personalized cancer care. The core Okomera Platform combines miniaturized tumor-on-chip technology and AI imaging to transform complex tumor biological responses into actionable treatment intelligence. The platform enables clinicians and drug developers to test up to 800 different conditions on 1000 microtumors from patient-derived biopsies, delivering results in under a week with only 50 cells needed. Applications span drug development, preclinical studies, and clinical decision-making, covering use cases including CRISPR screening, T-Cell Potency testing, and drug screening.

Differentiator

Problem solved

Functional benefit

Products and services

  • Okomera Platform Functional precision medicine platform combining miniaturized tumor-on-chip technology with AI imaging to test up to 800 conditions on 1000 microtumors from patient-derived biopsies, returning personalized drug response patterns in under one week from as few as 50 cells. Targeted at pharmaceutical and biotech drug developers, academic cancer researchers, and clinical oncology institutions for drug discovery, preclinical studies, and clinical decision-making applications including CRISPR screening, T-Cell Potency testing, and drug screening.
  • Drug Discovery Services Preclinical drug screening services using patient-derived organoids and spheroids to help pharmaceutical and biotech companies identify effective cancer treatments, evaluate drug efficacy, and identify therapeutic targets with high-throughput microfluidic screening. Customers contract for project-based screening engagements on the Okomera Platform.
  • Clinical Decision Support (Personalized Treatment Intelligence) Recurring personalized treatment intelligence service for clinicians and cancer centers that delivers patient-specific drug response patterns from biopsy material to guide cancer therapy selection and address the roughly 50% first-line treatment failure rate. Sold on a recurring basis to hospitals and clinical oncology institutions.

Quantifiable outcome

  • 1-week turnaround from biopsy to treatment decision
  • +4 more outcomes

Companies that use Okomera

Customer profile

Segments3 records

Ideal customer profiles3 records

Okomera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Okomera partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and major.

  • CRCM (Centre de Recherche en Cancérologie de Marseille)coreStrategic or Co-development Partner · 21 October 2024Cancer research center in Marseille collaborating on the development of novel CRISPR screening assay for cancer drug discovery using microfluidics and AI integration.
  • Ecole PolytechniquecoreStrategic or Co-development PartnerAcademic research partner contributing breakthrough science and technology foundations for Okomera's platform. Provides ongoing research collaboration and access to scientific expertise in microfluidics and bioengineering.
  • Institut PasteurcoreStrategic or Co-development PartnerAcademic research partner providing foundational scientific research for Okomera's tumor-on-chip technology. Key source of breakthrough science in cancer biology and organoid research.
  • Institut CuriecoreStrategic or Co-development PartnerLeading French cancer research center and university hospital. Strategic partner for clinical validation and research collaboration in oncology applications.
  • Gustave Roussy Cancer CampuscoreStrategic or Co-development PartnerPremier European cancer research and treatment center. Strategic partner for clinical applications and validation of personalized medicine approaches.
  • Cancer Research UKmajorStrategic or Co-development PartnerMajor UK-based cancer research charity and funder. Research partner for cancer biology studies and drug discovery applications.
  • University of California, BerkeleymajorStrategic or Co-development PartnerUS academic partner for research collaboration in bioengineering and cancer technology applications.

Scale indicators7 records

Recent moves3 records

Expansion highlights4 records

Okomera competitors and assessment

Company assessment

Direct peers

  • Mimetas: Dutch organ-on-chip company offering microfluidic 3D tissue models for drug discovery and toxicity screening. Closest direct competitor to Okomera in droplet-microfluidics and organoid-based drug response testing, serving the same pharma/biotech buyer set.
  • Emulate: US organ-on-chip platform using microfluidic 'chips' to model human organ biology for pharmaceutical R&D. Comparable in combining microfluidic chips with biological assays and AI/ML readout for drug discovery, targeting similar enterprise pharma customers.
  • CN Bio Innovations: UK-based organ-on-chip company with single- and multi-organ microphysiological systems used for drug discovery and disease modeling. Overlaps directly with Okomera in microfluidic platforms for preclinical drug screening and human-relevant disease models.
  • InSphero: Swiss 3D organoid and spheroid screening company offering high-throughput in vitro models for drug discovery and safety assessment. Directly comparable to Okomera's use of patient-derived spheroids for drug response testing and preclinical applications.
  • Hubrecht Organoid Technology (HUB): Dutch pioneer of adult stem cell-derived organoids, offering organoid biobanks and drug screening services. Comparable to Okomera in applying patient-derived organoids to functional precision medicine and oncology drug response prediction.

Broad incumbents

  • Crown Bioscience: Global preclinical CRO offering oncology services including organoid and PDX drug screening for pharma/biotech customers. Comparable buyer set and oncology drug-discovery use cases, but broader portfolio including in vivo models and clinical CRO services.
  • Tempus Labs: US precision oncology company combining molecular profiling, AI, and clinical data to support therapy selection in oncology. Overlaps with Okomera in AI-enabled personalized oncology decision support, but at much larger scale and with DNA/molecular rather than functional assay approaches.
  • Foundation Medicine: Genomics-driven oncology diagnostics company (Roche subsidiary) providing molecular profiling to guide cancer therapy. Comparable in serving the personalized oncology therapy-selection use case that Okomera targets, though via molecular rather than functional assays.

Emerging players

  • CytoReason: Israel-based AI drug discovery company using machine-learning models trained on proprietary biological data to support pharma R&D and target identification. Comparable emerging player applying AI to accelerate oncology drug discovery, with potential to converge with functional assay providers like Okomera.

Regional players

  • Molecular Partners: Swiss clinical-stage biotech developing DARPin-based therapeutics for oncology, with adjacent interest in functional cancer biology. Comparable in operating in the European precision oncology ecosystem and engaging the same pharma and academic partners as Okomera, though focused on therapeutic development rather than screening platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Okomera social profiles

Digital presence

Okomera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Okomera leadership team

Management profile

Number of profiles

Profiles4 records

Okomera funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Okomera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Okomera

What does Okomera do?

Okomera develops and operates a functional precision medicine platform that combines miniaturized tumor-on-chip microfluidic technology with AI imaging analysis to deliver rapid, personalized drug response testing from patient-derived biopsies. The platform serves pharmaceutical and biotech companies for preclinical drug screening and cancer research, and supports clinical oncologists with treatment selection intelligence, returning results in under one week from as few as 50 cells.

Is Okomera a public or private company?

Okomera is a private company. It is classified as venture growth investor backed and is currently operating.

When was Okomera founded?

Okomera was founded in 2020. It employs 11 to 50 people.

Where is Okomera based?

Okomera is headquartered in Paris, France, in the Europe region.

How does Okomera make money?

Two revenue lines are on record. Drug Discovery Services are the primary driver. The others are clinical Decision Support.

Who are Okomera's main competitors?

Direct peers on record are Mimetas, Emulate, CN Bio Innovations, InSphero and Hubrecht Organoid Technology (HUB). Broad incumbents are Crown Bioscience, Tempus Labs and Foundation Medicine. CytoReason is listed as an emerging player. Molecular Partners is listed as a regional player.

Does Okomera have an API?

No public API is recorded for Okomera.

What industry is Okomera in?

Okomera's product category is Functional Precision Medicine. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAANAE, Clinical Decision Support & Workflow Integration (EHR/oncology systems). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LelezardOkomera annonce un accord commercial avec Servier pour utiliser sa technologie de miniaturisation de tumeurs dans la recherche contre le cancerOkomera signed a commercial agreement with Servier to use its tumor miniaturization technology for cancer drug development. The platform will help reduce the high attrition rate of oncology candidates, with Servier using it autonomously for research on pancreatic cancer and glioblastoma.Business Wire BlogOkomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer ResearchOkomera signed a commercial agreement with Servier to use its tumor miniaturization technology for cancer research. Servier will operate the platform independently to evaluate new therapies, with applications for pancreatic cancer and glioblastoma. The deal marks Okomera's first commercial agreement with an international pharmaceutical group.FinancialContent Business PageOkomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer ResearchOkomera signed a commercial agreement with Servier to use its tumor miniaturization technology for cancer research. Servier will operate the platform independently to evaluate therapeutic approaches, focusing on pancreatic cancer and glioblastoma. The collaboration marks Okomera's first commercial deal with an international pharmaceutical group.Les Echos« C'est un jalon majeur dans la vie de notre société » : Okomera signe avec Servier pour industrialiser ses mini-tumeurs sur puceOkomera, a spin-off from the École polytechnique and Pasteur Institute, signed a partnership with Servier to commercialize its mini-tumor-on-chip technology. Servier will install and use the machine autonomously to evaluate new therapeutic avenues in oncology and immuno-oncology, including pancreatic cancer and glioblastoma.FinancialContent Business PageOkomera Strengthens Its Leadership Team With the Appointment of Marion Ghibaudo as Chief Technology OfficerOkomera appointed Marion Ghibaudo as Chief Technology Officer, reporting to CEO Silvère Lucquin, and moved Raphaël Tomasi to VP Platform. Ghibaudo brings over 20 years of medtech experience from GenSight Biologics and Mauna Kea Technologies. The move supports Okomera's industrial deployment of its tumor mini-avatars and AI platform.PR NewswireOkomera to Present Automated Desktop Organoid Screening Instrument for Oncology Drug Discovery at SLAS 2025 in San DiegoOkomera, a Paris-based biotech startup founded in 2020 as a spin-off from École Polytechnique, is presenting its Automated Desktop Organoid Screening Instrument at SLAS 2025 in San Diego from January 25-29, 2025. The platform combines proprietary microfluidic chips with AI-powered software to enable high-throughput preclinical drug testing and functional precision oncology research. The company will present a poster on results from a collaboration with researchers at Gustave Roussy demonstrating the platform's ability to generate reproducible 3D organoids from patient-derived xenografts and screen multiple drugs for breast cancer treatment.PR NewswireOkomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target ValidationOkomera received a €1.5 million grant from Bpifrance to develop and standardize a CRISPR screening assay for oncology drug discovery, in collaboration with the CRCM cancer research center. The platform uses droplet-microfluidics and AI to screen patient-derived organoids, with support from AstraZeneca.PR NewswireOkomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target ValidationOkomera has secured a €1.5 million grant from Bpifrance to develop and standardize a CRISPR screening assay for drug discovery in oncology. The company will collaborate with the Cancer Research Center of Marseille (CRCM) to integrate this technology into its automated microfluidics and AI-powered organoid screening platform. AstraZeneca is also recognized for its support in the successful grant application process.NeogapNeogap secures Eurostars funding to develop T-cell activity analysis – NEOGAPSwedish biotech Neogap Therapeutics has secured SEK 5 million in Eurostars funding to collaborate with French company Okomera on developing an analysis method for T-cell activity against tumors. This partnership aims to enhance the assessment of Neogap's pTTL cell therapy, currently in phase I/II trials for colorectal cancer, by utilizing Okomera’s innovative killing assay technology.MaddynessCancer : Okomera lève 10,2 M€ pour développer la médecine personnaliséeOkomera, a French biotech, raised €10.2M in seed funding to industrialize its AI-powered device that tests cancer treatments on tumor biopsies. The round, led by Résonance, aims to move from proof of concept to clinical validation, with a target market launch by 2028-2029.